Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for severe bleeding in hereditary hemorrhagic telangiectasia
2010-020545-26Phase 2Active
- Sponsor
- Policlinico di Bari
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in hereditary hemorrhagic telangiectasia (HHT), sponsored by Policlinico di Bari. Primary endpoints: Hemoglobin concentration, Evolution of pulmonary and hepatic fistulas and 1 more. Started Sep 2010; status: active.
02
Drugs
bevacizumab
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on 2010-020545-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020545-26.